Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy.

Claus C, Ferrara C, Xu W, Sam J, Lang S, Uhlenbrock F, Albrecht R, Herter S, Schlenker R, Hüsser T, Diggelmann S, Challier J, Mössner E, Hosse RJ, Hofer T, Brünker P, Joseph C, Benz J, Ringler P, Stahlberg H, Lauer M, Perro M, Chen S, Küttel C, Bhavani Mohan PL, Nicolini V, Birk MC, Ongaro A, Prince C, Gianotti R, Dugan G, Whitlow CT, Solingapuram Sai KK, Caudell DL, Burgos-Rodriguez AG, Cline JM, Hettich M, Ceppi M, Giusti AM, Crameri F, Driessen W, Morcos PN, Freimoser-Grundschober A, Levitsky V, Amann M, Grau-Richards S, von Hirschheydt T, Tournaviti S, Mølhøj M, Fauti T, Heinzelmann-Schwarz V, Teichgräber V, Colombetti S, Bacac M, Zippelius A, Klein C, Umaña P.

Sci Transl Med. 2019 Jun 12;11(496). pii: eaav5989. doi: 10.1126/scitranslmed.aav5989.

PMID:
31189721
2.

Prediction of the Optimal Dosing Regimen Using a Mathematical Model of Tumor Uptake for Immunocytokine-Based Cancer Immunotherapy.

Ribba B, Boetsch C, Nayak T, Grimm HP, Charo J, Evers S, Klein C, Tessier J, Charoin JE, Phipps A, Pisa P, Teichgräber V.

Clin Cancer Res. 2018 Jul 15;24(14):3325-3333. doi: 10.1158/1078-0432.CCR-17-2953. Epub 2018 Feb 20.

3.

Girdin (GIV) Expression as a Prognostic Marker of Recurrence in Mismatch Repair-Proficient Stage II Colon Cancer.

Ghosh P, Tie J, Muranyi A, Singh S, Brunhoeber P, Leith K, Bowermaster R, Liao Z, Zhu Y, LaFleur B, Tran B, Desai J, Jones I, Croxford M, Jover R, Goel A, Waring P, Hu S, Teichgraber V, Rohr UP, Ridder R, Shanmugam K, Gibbs P.

Clin Cancer Res. 2016 Jul 15;22(14):3488-98. doi: 10.1158/1078-0432.CCR-15-2290. Epub 2016 Mar 30.

4.

Immunohistochemical expression of HER2 in breast cancer: socioeconomic impact of inaccurate tests.

Vyberg M, Nielsen S, Røge R, Sheppard B, Ranger-Moore J, Walk E, Gartemann J, Rohr UP, Teichgräber V.

BMC Health Serv Res. 2015 Aug 29;15:352. doi: 10.1186/s12913-015-1018-6.

5.

Specific inhibition of fibroblast activation protein (FAP)-alpha prevents tumor progression in vitro.

Teichgräber V, Monasterio C, Chaitanya K, Boger R, Gordon K, Dieterle T, Jäger D, Bauer S.

Adv Med Sci. 2015 Sep;60(2):264-72. doi: 10.1016/j.advms.2015.04.006. Epub 2015 May 11.

PMID:
26057860
6.

5-Fluorouracil and interferon-α immunochemotherapy enhances immunogenicity of murine pancreatic cancer through upregulation of NKG2D ligands and MHC class I.

Khallouf H, Märten A, Serba S, Teichgräber V, Büchler MW, Jäger D, Schmidt J.

J Immunother. 2012 Apr;35(3):245-53. doi: 10.1097/CJI.0b013e31824b3a76.

PMID:
22421942
7.

Virus-specific CD8+ T cells upregulate programmed death-1 expression during acute friend retrovirus infection but are highly cytotoxic and control virus replication.

Zelinskyy G, Myers L, Dietze KK, Gibbert K, Roggendorf M, Liu J, Lu M, Kraft AR, Teichgräber V, Hasenkrug KJ, Dittmer U.

J Immunol. 2011 Oct 1;187(7):3730-7. doi: 10.4049/jimmunol.1101612. Epub 2011 Aug 26.

8.

Ceramide accumulation mediates inflammation, cell death and infection susceptibility in cystic fibrosis.

Teichgräber V, Ulrich M, Endlich N, Riethmüller J, Wilker B, De Oliveira-Munding CC, van Heeckeren AM, Barr ML, von Kürthy G, Schmid KW, Weller M, Tümmler B, Lang F, Grassme H, Döring G, Gulbins E.

Nat Med. 2008 Apr;14(4):382-91. doi: 10.1038/nm1748. Epub 2008 Mar 30.

9.

Strength of stimulus and clonal competition impact the rate of memory CD8 T cell differentiation.

Sarkar S, Teichgräber V, Kalia V, Polley A, Masopust D, Harrington LE, Ahmed R, Wherry EJ.

J Immunol. 2007 Nov 15;179(10):6704-14.

10.

Overexpression of acid sphingomyelinase sensitizes glioma cells to chemotherapy.

Grammatikos G, Teichgräber V, Carpinteiro A, Trarbach T, Weller M, Hengge UR, Gulbins E.

Antioxid Redox Signal. 2007 Sep;9(9):1449-56.

PMID:
17576160
11.

Percutaneous MR-guided radiofrequency ablation of recurrent sacrococcygeal chordomas.

Teichgräber V, Aubé C, Schmidt D, Jehle E, König C, Claussen CD, Pereira PL.

AJR Am J Roentgenol. 2006 Aug;187(2):571-4.

PMID:
16861565
12.

Ceramide-enriched membrane domains.

Bollinger CR, Teichgräber V, Gulbins E.

Biochim Biophys Acta. 2005 Dec 30;1746(3):284-94. Epub 2005 Sep 26. Review.

13.

Lineage relationship and protective immunity of memory CD8 T cell subsets.

Wherry EJ, Teichgräber V, Becker TC, Masopust D, Kaech SM, Antia R, von Andrian UH, Ahmed R.

Nat Immunol. 2003 Mar;4(3):225-34. Epub 2003 Feb 3.

PMID:
12563257
14.

High frequency of human cytomegalovirus (HCMV)-specific CD8+ T cells detected in a healthy CMV-seropositive donor.

Lang KS, Moris A, Gouttefangeas C, Walter S, Teichgräber V, Miller M, Wernet D, Hamprecht K, Rammensee HG, Stevanovic S.

Cell Mol Life Sci. 2002 Jun;59(6):1076-80.

PMID:
12169019
15.

Cutting edge: characterization of allorestricted and peptide-selective alloreactive T cells using HLA-tetramer selection.

Moris A, Teichgräber V, Gauthier L, Bühring HJ, Rammensee HG.

J Immunol. 2001 Apr 15;166(8):4818-21.

Supplemental Content

Loading ...
Support Center